BLTE - Belite Bio Inc - ADR
IEX Last Trade
48.785
0.325 0.666%
Share volume: 19,331
Last Updated: Fri 30 Aug 2024 09:59:31 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$48.46
0.33
0.67%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-0.47%
1 Month
-0.16%
3 Months
-0.14%
6 Months
6.29%
1 Year
50.43%
2 Year
79.56%
Key data
Stock price
$48.78
DAY RANGE
$47.62 - N/A
52 WEEK RANGE
$26.65 - $50.66
52 WEEK CHANGE
$0.48
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/08/2024
Company detail
CEO:
Region: US
Website:
Employees: 6
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website:
Employees: 6
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
belite bio inc is a san diego based clinical stage biopharmaceutical drug development company targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease and diabetes. developed from our anti-rbp4 technology platform, our lead candidate, lbs-008, is currently in a phase i clinical trial for dry age-related macular degeneration and its juvenile form, stargardt disease. lbs-008 has received orphan drug status in the us and europe, as well as rare pediatric disease status in the us.
Recent news